BioSpace News Archive

Augmedics, a pioneer in augmented reality surgical navigation, announced it has been named the successful bidder for the digital health assets of Surgalign and Holo Surgical following a competitive auction process.

Biohaven Ltd. (NYSE: BHVN; “Biohaven”) announced today that it received orphan medicinal product designation from the European Commission (EC) for taldefgrobep alfa, a novel anti-myostatin adnectin, for the treatment of spinal muscular atrophy (SMA).

Following the Company’s Fix, Fund, Propel approach, Navidea continues forward-focus to advance innovative technology to market while intending to appeal the potential delisting of its stock from the New York Stock Exchange (NYSE).

AppYea Inc., which is focused on the development of accurate wearable monitoring solutions to treat sleep apnea and snoring, announced the appointment of Adi Shemer as Chief Executive Officer of the Company.

In collaboration with Hackensack University Medical Center and Jersey Shore University Medical Center, Electro Cellular Healthcare Solutions, LLC, an affiliate of The Herrick Company, Inc, announces a new study treating patients with mild to moderate Alzheimer’s Dementia.

Seegene Inc., a leading South Korean company providing a total solution for PCR molecular diagnostics, took part in the 2023 American Association of Clinical Chemistry Annual Scientific Meeting & Clinical Lab Expo in California between July 25-27.

GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) in combination with carboplatin and paclitaxel, followed by Jemperli as a single agent for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR), as determined by an FDA-approved test, or microsatellite instability-high (MSI-H).

MannKind Corporation will release its 2023 second quarter financial results and year to date financial results and its management will host a conference call to discuss these results and corporate updates at 5:00 PM on Monday, August 7, 2023.

Defender Pharmaceuticals, Inc., a privately held life sciences company based in St. Louis, announced that it had entered into an exclusive license agreement with the U.S. Army Medical Materiel Development Activity, a subordinate laboratory of the U.S. Army.

Mineralys Therapeutics, Inc. (NASDAQ: MLYS) today announced it will report its financial results from the second quarter ended June 30, 2023, after the financial markets close on Monday, August 7, 2023.